[68Ga]Ga-DOTA-TOC PET/CT测定的肿瘤与肝脏比值作为兰瑞肽治疗高分化胃肠胰神经内分泌肿瘤疗效的预后因素
本研究为回顾性研究,纳入31例不可切除或转移性高分化胃肠胰神经内分泌肿瘤患者,在接受兰瑞肽前行[68Ga]Ga-DOTA-TOC PET/CT。中位无进展生存期为14.4个月,20例(64.5%)出现疾病进展。单因素分析中肿瘤与肝脏比值(TLR)、最大标准化摄取值(SUVmax)和全肿瘤体积(WTV)与无进展生存期显著相关,多因素分析仅TLR为独立预后因素(风险比3.182,95%CI 1.189-8.514,p=0.021)。结论认为低TLR可能是兰瑞肽治疗晚期高分化胃肠胰神经内分泌肿瘤预后较差的因素。
要点
- 兰瑞肽治疗高分化胃肠胰神经内分泌肿瘤的中位无进展生存期为14.4个月。
- 多因素分析中肿瘤与肝脏比值(TLR)是独立预后因素,风险比3.182(95%CI 1.189-8.514)。
- 单因素分析中TLR、SUVmax和WTV与无进展生存期显著相关。
核心结论
- 低肿瘤与肝脏比值(TLR)可能是兰瑞肽治疗晚期高分化胃肠胰神经内分泌肿瘤患者预后较差的因素。
研究设计与样本
- 回顾性研究纳入31例不可切除或转移性高分化胃肠胰神经内分泌肿瘤患者,均接受兰瑞肽治疗并在治疗前行[68Ga]Ga-DOTA-TOC PET/CT。
主要发现
- 患者平均年龄55.1±15.5岁(范围16.0-81.0),最常见原发肿瘤部位为胰腺,其次为胃和直肠。
- 兰瑞肽治疗的中位无进展生存期为14.4个月(范围1.3-34.9),20例(64.5%)患者出现疾病进展。
- 单因素分析中TLR(<8.1 vs ≥8.1;p=0.013)、SUVmax(<42.9 vs ≥42.9;p=0.037)和WTV(≥58.9 cm³ vs <58.9 cm³;p=0.030)与无进展生存期显著相关。
- 多因素分析中仅TLR为无进展生存期的独立因素(风险比3.182,95%CI 1.189-8.514,p=0.021)。
关键数值与推荐
- TLR<8.1 vs ≥8.1与无进展生存期显著相关(p=0.013)。
- SUVmax<42.9 vs ≥42.9与无进展生存期显著相关(p=0.037)。
- WTV≥58.9 cm³ vs <58.9 cm³与无进展生存期显著相关(p=0.030)。
- 多因素分析中TLR为独立预后因素,风险比3.182(95%CI 1.189-8.514),p=0.021。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lanreotide is a long-acting somatostatin analogue with proven antitumour effects against well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). However, there are no globally established prognostic factors associated with the efficacy of lanreotide as a treatment for GEP-NETs. We investigated the prognostic value of [68Ga]Ga-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) somatostatin receptor imaging for patients with WD GEP-NETs treated with lanreotide. METHODS: In this retrospective study, we included 31 patients with unresectable or metastatic WD GEP-NETs who received lanreotide and underwent [68Ga]Ga-DOTA-TOC PET/CT before receiving lanreotide. We captured the following clinicopathological variables: Eastern Cooperative Oncology Group (ECOG) performance status, primary tumour site, NET World Health Organization grade, existence of carcinoid symptoms, previous surgery, previous chemotherapy, and hepatic tumour volume assessed by CT or magnetic resonance imaging (MRI). We also assessed the following [68Ga]Ga-DOTA-TOC PET/CT variables: Krenning score, tumour-to-liver ratio (TLR), maximum standardized uptake value (SUVmax), whole tumour volume (WTV), and total receptor expression (TRE, WTV multiplied by SUVmean). The associations between these markers and progression-free survival (PFS) with lanreotide were analysed. RESULTS: The mean age was 55.1 ± 15.5 years (range 16.0-81.0). The most common primary tumour site was the pancreas, followed by the stomach, and rectum. The median PFS interval with lanreotide was 14.4 months (range 1.3-34.9), with identified disease progression in 20 patients (64.5%). Among the [68Ga]Ga-DOTA-TOC PET/CT variables, TLR (< 8.1 vs. ≥ 8.1; p = 0.013), SUVmax (< 42.9 vs. ≥ 42.9; p = 0.037), and WTV (≥ 58.9 cm3 vs. < 58.9 cm3; p = 0.030) were significantly associated with PFS in the univariate analyses, but only TLR (hazard ratio 3.182 [95% CI 1.189-8.514], p = 0.021) remained an independent factor for PFS in the multivariate analysis. CONCLUSIONS: Low TLR, determined via [68Ga]Ga-DOTA-TOC PET/CT, can be a factor of worse prognosis in patients with advanced WD GEP-NETs treated with lanreotide.
引用
- Kim YI, Yoo C, Oh SJ, et al. Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res. 2020. PMID: 32542576. doi:10.1186/s13550-020-00651-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。